These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15479215)

  • 21. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hypertension therapy for type 2 diabetics].
    Bönner G
    MMW Fortschr Med; 2007 Jun; 149(23):45, 47-8. PubMed ID: 18062579
    [No Abstract]   [Full Text] [Related]  

  • 23. Anti-diabetic effect of blockade of the renin-angiotensin system.
    Ando K; Fujita T
    Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
    Abuissa H; Jones PG; Marso SP; O'Keefe JH
    J Am Coll Cardiol; 2005 Sep; 46(5):821-6. PubMed ID: 16139131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of ACE inhibitors on diabetic patients without renal disease.
    Kirpichnikov D; Winer N; Sowers JR
    Curr Diab Rep; 2002 Feb; 2(1):21-5. PubMed ID: 12643119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
    McCall KL; Craddock D; Edwards K
    Pharmacotherapy; 2006 Sep; 26(9):1297-306. PubMed ID: 16945052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular and metabolic benefits of ACE inhibition: moving beyond blood pressure reduction.
    Gerstein HC
    Diabetes Care; 2000 Jul; 23(7):882-3. PubMed ID: 10895833
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].
    Ceconi C; Mastrorilli F; Squasi PA; Gaitani S; Guardigli G; Ferrari R
    Ital Heart J; 2005 Nov; 6 Suppl 7():5S-13S. PubMed ID: 16485512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should you put all diabetic patients on statins?
    Leiter LA
    J Fam Pract; 2007 Apr; 56(4):294-300. PubMed ID: 17403328
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pharmacological prevention of late complications of diabetes].
    Jensen TJ; Hilsted JC
    Ugeskr Laeger; 1996 Apr; 158(17):2402-3. PubMed ID: 8685997
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
    Andraws R; Brown DL
    Am J Cardiol; 2007 Apr; 99(7):1006-12. PubMed ID: 17398202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Type 2 diabetes. Routine ACE inhibitors?].
    Hönl SB
    Med Monatsschr Pharm; 2008 Apr; 31(4):149-50. PubMed ID: 18497249
    [No Abstract]   [Full Text] [Related]  

  • 34. Prospects for angiotensin receptor blockers in diabetic retinopathy.
    Sjølie AK
    Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S31-9. PubMed ID: 17321627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The CARDS Study: cardiovascular primary prevention in diabetes patients using Atorvastin].
    Griebenow R
    Internist (Berl); 2005 Mar; 46(3):350-2. PubMed ID: 15696286
    [No Abstract]   [Full Text] [Related]  

  • 36. ARBs vs ACE inhibitors for preventing diabetic nephropathy.
    Greenwood V
    J Fam Pract; 2005 May; 54(5):453; discussion 453-4. PubMed ID: 15865904
    [No Abstract]   [Full Text] [Related]  

  • 37. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M
    Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Point: If it is important to prevent type 2 diabetes, it is important to consider all proven therapies within a comprehensive approach.
    Gerstein HC
    Diabetes Care; 2007 Feb; 30(2):432-4. PubMed ID: 17259525
    [No Abstract]   [Full Text] [Related]  

  • 39. Summaries for patients. The cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for patients with diabetes.
    Ann Intern Med; 2005 Jul; 143(2):I21. PubMed ID: 16027445
    [No Abstract]   [Full Text] [Related]  

  • 40. The ADVANCE trial.
    Procopiou M
    Lancet; 2008 Jan; 371(9606):25; author reply 26. PubMed ID: 18177767
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.